2,051 results on '"Albarello L"'
Search Results
2. OC.18.11: LONG-TERM OUTCOMES OF MAINTENANCE THERAPY IN ADULT AND PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A SYSTEMATIC REVIEW AND METANALYSIS
- Author
-
Barchi, A., primary, Mandarino, F.V., additional, Dell'Anna, G., additional, Fasulo, E., additional, Yacoub, M., additional, Albarello, L., additional, Massimino, L., additional, Ungaro, F., additional, Savarino, E.V., additional, Passaretti, S., additional, Danese, S., additional, and Vespa, E., additional
- Published
- 2024
- Full Text
- View/download PDF
3. From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis.
- Author
-
Barchi A, Mandarino FV, Yacoub MR, Albarello L, Massimino L, Savarino EV, Ungaro F, Passaretti S, Masclee GMC, Danese S, Bredenoord AJ, and Vespa E
- Subjects
- Humans, Inflammation drug therapy, Animals, Antibodies, Monoclonal therapeutic use, Dermatitis, Atopic drug therapy, Dermatitis, Atopic immunology, Dermatitis, Atopic pathology, Eosinophilic Esophagitis drug therapy, Eosinophilic Esophagitis pathology, Th2 Cells immunology, Th2 Cells metabolism
- Abstract
Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus. EoE shares a common pathogenetic mechanism with other chronic disorders pertaining to the type 2 inflammatory spectrum, such as atopic dermatitis (AD), allergic rhinitis (AR), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The recent advancements in EoE pathogenesis understanding have unveiled new molecular targets implied within the "atopic march" picture as well as specific to EoE. These discoveries have led to the clinical evaluation of several novel drugs (monoclonal antibodies and immune modulators), specifically aimed at the modulation of Th2 inflammation. In this comprehensive review, we have focused on the subtle mechanisms of type 2 inflammatory disorders, highlighting the similarities and differences with EoE, taking a deeper look into the evolving field of biologic therapies, already approved or under current investigation.
- Published
- 2024
- Full Text
- View/download PDF
4. S100 protein is commonly expressed in neuroendocrine tumours of major and minor ampulla.
- Author
-
Vanoli A, Inzani F, Parente P, Albarello L, Fassan M, Grillo F, Messina A, Carlino A, Uccella S, Spaggiari P, La Rosa S, and Rindi G
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
5. Could early tumour volume changes assessed on morphological MRI predict the response to chemoradiation therapy in locally-advanced rectal cancer?
- Author
-
Palmisano, A., Esposito, A., Di Chiara, A., Ambrosi, A., Passoni, P., Slim, N., Fiorino, C., Albarello, L., Di Muzio, N., Calandrino, R., Rosati, R., Del Maschio, A., and De Cobelli, F.
- Published
- 2018
- Full Text
- View/download PDF
6. PO-1355 Impact of lymphopenia in patients with esophageal cancer after neoadjuvant chemoradiotherapy
- Author
-
SLIM, N., primary, Chissotti, C., additional, Passoni, P., additional, Tummineri, R., additional, Zerbetto, F., additional, Torrisi, M., additional, Giannini, L., additional, Midulla, M., additional, Ferrario, F., additional, Villa, S., additional, Mazza, E., additional, Albarello, L., additional, De Cobelli, F., additional, Rosati, R., additional, Cascinu, S., additional, and Di Muzio, N.G., additional
- Published
- 2023
- Full Text
- View/download PDF
7. The Dual Lens of Endoscopy and Histology in the Diagnosis and Management of Eosinophilic Gastrointestinal Disorders-A Comprehensive Review.
- Author
-
Barchi A, Vespa E, Passaretti S, Dell'Anna G, Fasulo E, Yacoub MR, Albarello L, Sinagra E, Massimino L, Ungaro F, Danese S, and Mandarino FV
- Abstract
Eosinophilic Gastrointestinal Disorders (EGIDs) are a group of conditions characterized by abnormal eosinophil accumulation in the gastrointestinal tract. Among these EGIDs, Eosinophilic Esophagitis (EoE) is the most well documented, while less is known about Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), and Eosinophilic Colitis (EoC). The role of endoscopy in EGIDs is pivotal, with applications in diagnosis, disease monitoring, and therapeutic intervention. In EoE, the endoscopic reference score (EREFS) has been shown to be accurate in raising diagnostic suspicion and effective in monitoring therapeutic responses. Additionally, endoscopic dilation is the first-line treatment for esophageal strictures. For EoG and EoN, while the literature is more limited, common endoscopic findings include erythema, nodules, and ulcerations. Histology remains the gold standard for diagnosing EGIDs, as it quantifies eosinophilic infiltration. In recent years, there have been significant advancements in the histological understanding of EoE, leading to the development of diagnostic scores and the identification of specific microscopic features associated with the disease. However, for EoG, EoN, and EoC, precise eosinophil count thresholds for diagnosis have not yet been established. This review aims to elucidate the role of endoscopy and histology in the diagnosis and management of the three main EGIDs and to analyze their strengths and limitations, their interconnection, and future research directions.
- Published
- 2024
- Full Text
- View/download PDF
8. OC.03.2 YOUNG-ONSET GASTRIC CANCERS ARE OFTEN EARLY GASTRIC CANCERS
- Author
-
Puzzono, M., primary, Mannucci, A., additional, Poliani, L., additional, Iacopino, L., additional, Albarello, L., additional, and Cavestro, G.M., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases.
- Author
-
Vanoli A, Grami O, Klersy C, Milanetto AC, Albarello L, Fassan M, Luchini C, Grillo F, Spaggiari P, Inzani F, Uccella S, Parente P, Nappo G, Mattiolo P, Milione M, Pietrabissa A, Cobianchi L, Schiavo Lena M, Partelli S, Di Sabatino A, Sempoux C, Capella C, Pasquali C, Doglioni C, Sessa F, Scarpa A, Rindi G, Paulli M, Zerbi A, Falconi M, Solcia E, and La Rosa S
- Subjects
- Humans, Infant, Newborn, Prognosis, Carcinoma, Neuroendocrine pathology, Neuroendocrine Tumors pathology, Pancreatic Neoplasms pathology
- Abstract
Neuroendocrine neoplasms (NENs) of the major and minor ampulla are rare diseases with clinico-pathologic features distinct from non-ampullary-duodenal NENs. However, they have been often combined and the knowledge on prognostic factors specific to ampullary NENs (Amp-NENs) is limited. The aim of this study was to identify factors associated with metastatic potential and patient prognosis in Amp-NENs. We clinically and histologically investigated an international series of 119 Amp-NENs, comprising 93 ampullary neuroendocrine tumors (Amp-NETs) and 26 neuroendocrine carcinomas (Amp-NECs). Somatostatin-producing tubulo-acinar NET represented the predominant Amp-NET histologic subtype (58 cases, 62%, 12 associated with type 1 neurofibromatosis). Compared to Amp-NETs, Amp-NECs arose in significantly older patients and showed a larger tumor size, a more frequent small vessel invasion, a deeper level of invasion and a higher rate of distant metastasis, and, importantly, a tremendously worse disease-specific patient survival. In Amp-NETs, the WHO grade proved to be a strong predictor of disease-specific survival (hazard ratio: 12.61, p < 0.001 for G2 vs G1), as well as patient age at diagnosis > 60 years, small vessel invasion, pancreatic invasion, and distant metastasis at diagnosis. Although nodal metastatic disease was not associated with survival by itself, patients with > 3 metastatic lymph nodes showed a worse outcome in comparison with the remaining Amp-NET cases with lymphadenectomy. Tumor epicenter in the major ampulla, small vessel invasion, and tumor size > 16 mm were independent predictors of nodal metastases in Amp-NETs. In conclusion, we identified prognostic factors, which may eventually help guide treatment decisions in Amp-NENs., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
10. Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
- Author
-
Potenza A, Balestrieri C, Spiga M, Albarello L, Pedica F, Manfredi F, Cianciotti BC, De Lalla C, Botrugno OA, Faccani C, Stasi L, Tassi E, Bonfiglio S, Scotti GM, Redegalli M, Biancolini D, Camisa B, Tiziano E, Sirini C, Casucci M, Iozzi C, Abbati D, Simeoni F, Lazarevic D, Elmore U, Fiorentini G, Di Lullo G, Casorati G, Doglioni C, Tonon G, Dellabona P, Rosati R, Aldrighetti L, Ruggiero E, and Bonini C
- Subjects
- Humans, Receptors, Antigen, T-Cell, Cell Engineering, Colorectal Neoplasms pathology, Colorectal Neoplasms therapy, Liver Neoplasms secondary, Liver Neoplasms therapy, T-Lymphocytes, Apyrase genetics, Antigens, CD genetics
- Abstract
Objective: Colorectal tumours are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumour progression but are burdened by immunosuppressive signals, which might vary from primary to metastatic stages. Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases, and genome editing tools to develop CRC-specific engineered T cells., Design: We paired high-dimensional flow cytometry, RNA sequencing and immunohistochemistry to describe the functional phenotype of T cells from healthy and neoplastic tissue of patients with primary and metastatic CRC and we applied lentiviral vectors (LV) and CRISPR/Cas9 genome editing technologies to develop CRC-specific cellular products., Results: We found that T cells are mainly localised at the front edge and that tumor-infiltrating T cells co-express multiple inhibitory receptors, which largely differ from primary to metastatic sites. Our data highlighted CD39 as the major driver of exhaustion in both primary and metastatic colorectal tumours. We thus simultaneously redirected T-cell specificity employing a novel T-cell receptor targeting HER-2 and disrupted the endogenous TCR genes (TCR editing (TCR
ED )) and the CD39 encoding gene ( ENTPD1 ), thus generating TCRED ENTPD1KO HER-2-redirected lymphocytes. We showed that the absence of CD39 confers to HER-2-specific T cells a functional advantage in eliminating HER-2+ patient-derived organoids in vitro and in vivo ., Conclusion: HER-2-specific CD39 disrupted engineered T cells are promising advanced medicinal products for primary and metastatic CRC., Competing Interests: Competing interests: CBo has been member of Advisory Board and Consultant for Intellia, TxCell, Novartis, GSK, Allogene, Kite/Gilead, Kiadis, Evir, Janssen, Genyo, Epsilen and received research support from Intellia Therapeutics. AP, PDB, GC, ER, BCC and CBo are inventors on different patents on cancer immunotherapy and genetic engineering., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2023
- Full Text
- View/download PDF
11. Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma.
- Author
-
Arbore G, Albarello L, Bucci G, Punta M, Cossu A, Fanti L, Maurizio A, Di Mauro F, Bilello V, Arrigoni G, Bonfiglio S, Biancolini D, Puccetti F, Elmore U, Vago L, Cascinu S, Tonon G, Rosati R, Casorati G, and Dellabona P
- Subjects
- Humans, Neoadjuvant Therapy, Retrospective Studies, Adenocarcinoma pathology, Esophageal Neoplasms pathology
- Abstract
Current treatment for patients with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy (nCT), alone or combined with radiotherapy, before surgery. However, fewer than 30% of treated patients show a pathologic complete response to nCT, which correlates with increased 5-year survival compared with nonresponders. Understanding the mechanisms of response to nCT is pivotal to better stratify patients and inform more efficacious therapies. Here, we investigated the immune mechanisms involved in nCT response by multidimensional profiling of pretreatment tumor biopsies and blood from 68 patients with EAC (34 prospectively and 34 retrospectively collected), comparing complete responders versus nonresponders to nCT. At the tumor level, complete response to nCT was associated with molecular signatures of immune response and proliferation, increased putative antitumor tissue-resident memory CD39+ CD103+ CD8+ T cells, and reduced immunosuppressive T regulatory cells (Treg) and M2-like macrophages. Systemically, complete responders showed higher frequencies of immunostimulatory CD14+ CD11c+ HLA-DRhigh cells, and reduced programmed cell death ligand 1-positive (PD-L1+) monocytic myeloid-derived suppressor cells, along with high plasma GM-CSF (proinflammatory) and low IL4, CXCL10, C3a, and C5a (suppressive). Plasma proinflammatory and suppressive cytokines correlated directly and inversely, respectively, with the frequency of tumor-infiltrating CD39+ CD103+ CD8+ T cells. These results suggest that preexisting immunity in baseline tumor drives the clinical activity of nCT in locally advanced EAC. Furthermore, it may be possible to stratify patients based on predictive immune signatures, enabling tailored neoadjuvant and/or adjuvant regimens., Significance: Multidimensional profiling of pretreatment esophageal adenocarcinoma shows patient response to nCT is correlated with active preexisting immunity and indicates molecular pathways of resistance that may be targeted to improve clinical outcomes., (©2023 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
12. Could perfusion heterogeneity at dynamic contrast-enhanced MRI be used to predict rectal cancer sensitivity to chemoradiotherapy?
- Author
-
Palmisano, A., Esposito, A., Rancoita, P.M.V., Di Chiara, A., Passoni, P., Slim, N., Campolongo, M., Albarello, L., Fiorino, C., Rosati, R., Del Maschio, A., and De Cobelli, F.
- Published
- 2018
- Full Text
- View/download PDF
13. 128: DECIPHERING THE IMMUNOLOGICAL DETERMINANTS OF RESPONSE TO NEOADJUVANT CHEMO-RADIATION IN ESOPHAGEAL ADENOCARCINOMA
- Author
-
Arbore, G, primary, Albarello, L, additional, Bucci, G, additional, Punta, M, additional, Bilello, V, additional, Bonfiglio, S, additional, Fanti, L, additional, Cossu, A, additional, Tonon, G, additional, Rosati, R, additional, Casorati, G, additional, and Dellabona, P, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Two individuals with potential monkeypox virus reinfection.
- Author
-
Raccagni AR, Canetti D, Mileto D, Tamburini AM, Candela C, Albarello L, Bracchitta F, Mancon A, Micheli V, Gismondo MR, Castagna A, and Nozza S
- Subjects
- Humans, Reinfection, Monkeypox virus genetics, Mpox (monkeypox) epidemiology
- Abstract
Competing Interests: DC has received research grants from Gilead Sciences and GlaxoSmithKline and received payment for educational events and support for attending meetings from Merck Sharp & Dohme and ViiV Healthcare. AC has received personal fees for advisory boards, speaker panels, and educational materials from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme, and Theratechnologies. SN has received personal fees for advisory boards, speaker panels, and educational materials from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, and Merck Sharp & Dohme. All other authors declare no competing interests. Individuals included in the study signed written informed consent to include case details, personal information, and images in the published version of the manuscript in all formats.
- Published
- 2023
- Full Text
- View/download PDF
15. Esophagus and Stomach: Is There a Role for MR Imaging?
- Author
-
De Cobelli F., Palumbo D., Albarello L., Rosati R., Giganti F., De Cobelli, F., Palumbo, D., Albarello, L., Rosati, R., and Giganti, F.
- Subjects
Magnetic resonance imaging ,Staging ,Prognosi ,Esophageal cancer ,Gastric cancer ,Treatment response - Abstract
MR imaging has been increasingly used in the diagnostic work-up of benign and malignant conditions of the gastroesophageal tract. The use of an adequate MR imaging protocol is crucial, although standardization of imaging studies is still far from being implemented. Research on MR imaging-based biomarkers show promising results in assessing tumor aggressiveness and prognosis, and in the evaluation of response to treatment, both in esophageal and gastric cancers.
- Published
- 2020
16. Correlations between Molecular Alterations, Histopathological Characteristics, and Poor Prognosis in Esophageal Adenocarcinoma.
- Author
-
Orsini A, Mastracci L, Bozzarelli I, Ferrari A, Isidori F, Fiocca R, Lugaresi M, D'Errico A, Malvi D, Cataldi-Stagetti E, Spaggiari P, Tomezzoli A, Albarello L, Ristimäki A, Bottiglieri L, Krishnadath KK, Rosati R, Fumagalli Romario U, De Manzoni G, Räsänen J, Martinelli G, Mattioli S, Bonora E, and On Behalf Of The Eacsge Consortium
- Abstract
Esophageal adenocarcinoma (EAC) is a severe malignancy with increasing incidence, poorly understood pathogenesis, and low survival rates. We sequenced 164 EAC samples of naïve patients (without chemo-radiotherapy) with high coverage using next-generation sequencing technologies. A total of 337 variants were identified across the whole cohort, with TP53 as the most frequently altered gene (67.27%). Missense mutations in TP53 correlated with worse cancer-specific survival (log-rank p = 0.001). In seven cases, we found disruptive mutations in HNF1alpha associated with other gene alterations. Moreover, we detected gene fusions through massive parallel sequencing of RNA, indicating that it is not a rare event in EAC. In conclusion, we report that a specific type of TP53 mutation (missense changes) negatively affected cancer-specific survival in EAC. HNF1alpha was identified as a new EAC-mutated gene.
- Published
- 2023
- Full Text
- View/download PDF
17. Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection
- Author
-
Sagnelli, C., Uberti-Foppa, C., Pasquale, G., De Pascalis, S., Coppola, N., Albarello, L., Doglioni, C., Lazzarin, A., and Sagnelli, E.
- Published
- 2013
- Full Text
- View/download PDF
18. P-158 Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma
- Author
-
Arbore, G., primary, Albarello, L., additional, Bucci, G., additional, Punta, M., additional, Bilello, V., additional, Fanti, L., additional, Cossu, A., additional, Tonon, G., additional, Rosati, R., additional, Casorati, G., additional, and Dellabona, P., additional
- Published
- 2021
- Full Text
- View/download PDF
19. Diagnostic interobserver variability in Crohn’s disease- and ulcerative colitis-associated dysplasia: a multicenter digital survey from the IG-IBD Pathologists Group
- Author
-
Leoncini, G., Donato, F., Reggiani-Bonetti, L., Salviato, T., Cadei, M., Daperno, M., Principi, M. B., Armuzzi, A., Caprioli, F., Canavese, G., Villanacci, V., Albarello, L., Andorno, A., Aprile, M. R., Aquilano, M. C., Baron, L., Battista, S., Becchina, G., Bellis, D., Biletta, E., D'Ambrosio, M. R., David, E., Del Sordo, R., Facchetti, M., Fortunato, M., Giustiniani, M. C., Piscitelli, D., Saragoni, L., and Tanzi, G.
- Subjects
Crohn’s disease ,medicine.medical_specialty ,Dysplasia ,Colorectal cancer ,Ulcerative ,Inflammatory bowel disease ,Gastroenterology ,Crohn Disease ,Internal medicine ,Biopsy ,medicine ,Humans ,Grading (tumors) ,Observer Variation ,Crohn's disease ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Inflammatory Bowel Diseases ,Colitis ,Ulcerative colitis ,digestive system diseases ,Colorectal surgery ,Pathologists ,Italy ,Neoplasm Recurrence, Local ,Colitis, Ulcerative ,Neoplasm Recurrence ,Local ,Surgery ,business - Abstract
Crohn’s disease (CD) and ulcerative colitis, two forms of inflammatory bowel disease (IBD), are chronic and relapsing conditions of the gastrointestinal tract both characterized by long lasting chronic inflammation and increased risk of dysplasia and colorectal cancer (CRC). The aim of our study was to evaluate the interobserver agreement about IBD-associated dysplasia among pathologists belonging to the Italian Group for Inflammatory Bowel Diseases (IG-IBD P). The present multicenter survey was performed using telepathology, supported by an open source E-learning platform. Biopsy specimens from 30 colonoscopies and from 20 patients were included. The glass slides of any case, including clinical and endoscopic data, were digitalized and uploaded on the E-learning platform. All the digital slides were grouped in 54 diagnostic “blocks”. Blinded histopathological evaluation on all the digital slides was performed by 20 gastrointestinal pathologists. Closed-ended questions about (1) the occurrence of IBD; (2) the classification of IBD (as UC or CD); (3) the presence of active versus quiescent disease; (4) the presence of dysplasia; (5) the possible association of dysplasia with the sites of disease (dysplasia-associated lesion or mass—DALM vs adenoma-like mass—ALM); (6) the grading of dysplasia according to the ECCO guidelines (negative, indefinite, low grade, high grade categories) and (7) the presence of associated serrated features, were proposed in each case. Inter-observer agreement was evaluated by mean agreement percentage and kappa statistic, when suitable. The diagnosis of IBD was confirmed in 19 of 20 patients, 17 of 19 being classified as UC, 2 as CD. The mean interobserver agreement percentages about (1) the evidence of IBD, (2) the presence of either UC or CD and (3) the activity grading resulted to be 80%, 69% and 86%, respectively. Dysplasia was detected in 8/20 patients, with moderate agreement between pathologists (mean 72%, k 0.48). Particularly, low grade dysplasia was found in 13 biopsies (combined k 0.38), whereas high grade dysplasia in 8 (combined k 0.47). When the endoscopic and histopathological data were combined, features consistent with DALM were found in 6 of 20 patients with low grade dysplasia and those consistent with ALM in 2 patients with low grade dysplasia in a single biopsy (mean agreement: 86%). An associated serrated pattern was discovered in 4 patients (7 biopsies). Our study showed moderate interobserver agreement about the histopathological detection and classification of IBD-associated dysplasia. Further efforts should be undertaken to integrate the histopathological data with both the ancillary tests and molecular investigations.
- Published
- 2021
20. No evidence of enteroviruses in the intestine of patients with type 1 diabetes
- Author
-
Mercalli, A., Lampasona, V., Klingel, K., Albarello, L., Lombardoni, C., Ekström, J., Sordi, V., Bolla, A., Mariani, A., Bzhalava, D., Dillner, J., Roivainen, M., Bosi, E., and Piemonti, L.
- Published
- 2012
- Full Text
- View/download PDF
21. Ghrelin-producing epsilon cells in the developing and adult human pancreas
- Author
-
Andralojc, K. M., Mercalli, A., Nowak, K. W., Albarello, L., Calcagno, R., Luzi, L., Bonifacio, E., Doglioni, C., and Piemonti, L.
- Published
- 2009
- Full Text
- View/download PDF
22. Neoadjuvant chemoradiotherapy in patients with esopageal or esophageal gastric junction cancer
- Author
-
Slim N., Tummineri R., Parise P., Mazza E., Albarello L., Puccetti F., Deli A. M., Incerti E., Azizi M., Dell'oca I., Cossu A., Reni M., Rosati R., Passoni P., Di Muzio N., Slim, N., Tummineri, R., Parise, P., Mazza, E., Albarello, L., Puccetti, F., Deli, A. M., Incerti, E., Azizi, M., Dell'Oca, I., Cossu, A., Reni, M., Rosati, R., Passoni, P., and Di Muzio, N.
- Published
- 2019
23. Sentinel node mapping during laparoscopic distal gastrectomy for gastric cancer
- Author
-
Orsenigo, E., Tomajer, V., Palo, S. Di, Albarello, L., Doglioni, C., Masci, E., Viale, E., and Staudacher, C.
- Published
- 2008
- Full Text
- View/download PDF
24. Arterial vs pancreatic phase: which is the best choice in the evaluation of pancreatic endocrine tumours with multidetector computed tomography (MDCT)?
- Author
-
Gusmini, S., Nicoletti, R., Martinenghi, C., Caborni, C., Balzano, G., Zerbi, A., Rocchetti, S. I., Arcidiacono, P. G., Albarello, L., De Cobelli, F., Di Carlo, V., and Del Maschio, A.
- Published
- 2007
- Full Text
- View/download PDF
25. P-289 Prognostic role of clinical and pathobiological factors in patients with locally advanced gastric and esophagogastric junction cancers: Potential implications in the post-operative strategy
- Author
-
Liscia, N., Albarello, L., Camera, S., Casadei-Gardini, A., Foti, S., Ronzoni, M., Spanu, D., Damascelli, A., Massaron, S., Treppiedi, E., Elmore, U., Puccetti, F., Cossu, A., Barbieri, L., Scartozzi, M., Cascinu, S., Rosati, R., and Mazza, E.
- Published
- 2023
- Full Text
- View/download PDF
26. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis.
- Author
-
Centonze G, Maisonneuve P, Prinzi N, Pusceddu S, Albarello L, Pisa E, Barberis M, Vanoli A, Spaggiari P, Bossi P, Cattaneo L, Sabella G, Solcia E, La Rosa S, Grillo F, Tagliabue G, Scarpa A, Papotti M, Volante M, Mangogna A, Del Gobbo A, Ferrero S, Rolli L, Roca E, Bercich L, Benvenuti M, Messerini L, Inzani F, Pruneri G, Busico A, Perrone F, Tamborini E, Pellegrinelli A, Kankava K, Berruti A, Pastorino U, Fazio N, Sessa F, Capella C, Rindi G, and Milione M
- Subjects
- Humans, Prognosis, Retrospective Studies, Ki-67 Antigen, Pancreatic Neoplasms pathology, Carcinoma, Neuroendocrine pathology, Neuroendocrine Tumors pathology, Stomach Neoplasms pathology
- Abstract
Introduction: Poorly differentiated neuroendocrine carcinomas (NECs) are characterized by aggressive clinical course and poor prognosis. No reliable prognostic markers have been validated to date; thus, the definition of a specific NEC prognostic algorithm represents a clinical need. This study aimed to analyze a large NEC case series to validate the specific prognostic factors identified in previous studies on gastro-entero-pancreatic and lung NECs and to assess if further prognostic parameters can be isolated., Methods: A pooled analysis of four NEC retrospective studies was performed to evaluate the prognostic role of Ki-67 cut-off, the overall survival (OS) according to primary cancer site, and further prognostic parameters using multivariable Cox proportional hazards model and machine learning random survival forest (RSF)., Results: 422 NECs were analyzed. The most represented tumor site was the colorectum (n = 156, 37%), followed by the lungs (n = 111, 26%), gastroesophageal site (n = 83, 20%; 66 gastric, 79%) and pancreas (n = 42, 10%). The Ki-67 index was the most relevant predictor, followed by morphology (pure or mixed/combined NECs), stage, and site. The predicted RSF response for survival at 1, 2, or 3 years showed decreasing survival with increasing Ki-67, pure NEC morphology, stage III-IV, and colorectal NEC disease. Patients with Ki-67 <55% and mixed/combined morphology had better survival than those with pure morphology. Morphology pure or mixed/combined became irrelevant in NEC survival when Ki-67 was ≥55%. The prognosis of metastatic patients who did not receive any treatment tended to be worse compared to that of the treated group. The prognostic impact of Rb1 immunolabeling appears to be limited when multiple risk factors are simultaneously assessed., Conclusion: The most effective parameters to predict OS for NEC patients could be Ki-67, pure or mixed/combined morphology, stage, and site., (© 2022 S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
27. Optical coherence tomography compared with histology of the main pancreatic duct structure in normal and pathological conditions: An ‘ex vivo study’
- Author
-
Testoni, P.A., Mangiavillano, B., Albarello, L., Mariani, A., Arcidiacono, P.G., Masci, E., and Doglioni, C.
- Published
- 2006
- Full Text
- View/download PDF
28. Main pancreatic duct, common bile duct and sphincter of Oddi structure visualized by optical coherence tomography: An ex vivo study compared with histology
- Author
-
Testoni, P.A., Mariani, A., Mangiavillano, B., Albarello, L., Arcidiacono, P.G., Masci, E., and Doglioni, C.
- Published
- 2006
- Full Text
- View/download PDF
29. TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study
- Author
-
Rindi, G., Falconi, M., Klersy, C., Albarello, L., Boninsegna, L., Buchler, M. W., Capella, C., Caplin, M., Couvelard, A., Doglioni, C., Delle Fave, G., Fischer, L., Fusai, G., de Herder, W. W., Jann, H., Komminoth, P., de Krijger, R. R., La Rosa, S., Luong, T. V., Pape, U., Perren, A., Ruszniewski, P., Scarpa, A., Schmitt, A., Solcia, E., and Wiedenmann, B.
- Published
- 2012
- Full Text
- View/download PDF
30. Rhodococcus equi colonic lesion mimicking colon cancer
- Author
-
De Nardi, P., Stratta, G., Fumagalli, L., Ferretti, F., Albarello, L., and Staudacher, C.
- Published
- 2011
- Full Text
- View/download PDF
31. MRI prediction of pathological response in locally advanced rectal cancer: when apparent diffusion coefficient radiomics meets conventional volumetry
- Author
-
Palmisano, A., primary, Di Chiara, A., additional, Esposito, A., additional, Rancoita, P.M.V., additional, Fiorino, C., additional, Passoni, P., additional, Albarello, L., additional, Rosati, R., additional, Del Maschio, A., additional, and De Cobelli, F., additional
- Published
- 2020
- Full Text
- View/download PDF
32. Pancreatic metastases from primary ileal NET only detected by 68Ga-DOTATOC PET/CT
- Author
-
Mapelli, P., primary, Fallanca, F., additional, Franchini, A., additional, Albarello, L., additional, Vanoli, E. G., additional, Partelli, S., additional, Muffatti, F., additional, Gianolli, L., additional, Falconi, M., additional, and Picchio, M., additional
- Published
- 2020
- Full Text
- View/download PDF
33. Optical coherence tomography in the diagnosis of coeliac disease: a preliminary report
- Author
-
Masci, E, Mangiavillano, B, Albarello, L, Mariani, A, Doglioni, C, and Testoni, P A
- Published
- 2006
34. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy.
- Author
-
Rossi G, Petrone MC, Schiavo Lena M, Albarello L, Palumbo D, Testoni SGG, Archibugi L, Tacelli M, Zaccari P, Vanella G, Apadula L, Crippa S, Belfiori G, Reni M, Falconi M, Doglioni C, De Cobelli F, Healey AJ, Capurso G, and Arcidiacono PG
- Abstract
Objective: Endoscopic ultrasound (US)-guided radiofrequency ablation (RFA) has been investigated for pancreatic ductal adenocarcinoma (PDAC) but studies are limited and heterogeneous. Computed tomography (CT) scan features may predict RFA response after chemotherapy but their role is unexplored. The primary aim was to investigate the efficacy of ex-vivo application of a dedicated RFA system at three power on surgically resected PDAC in patients who underwent neoadjuvant chemotherapy. The secondary aim was to explore the association between pre-treatment CT-based quantitative features and RFA response., Methods: Fifteen ex-vivo PDAC samples were treated by RFA under US control at three power groups (10, 30, and 50 W). Short axis necrosis diameter was measured by two expert blinded pathologists as the primary outcome. Two radiologists independently reviewed preoperative CT images., Results: Eighty percent of specimens showed coagulative necrosis consisting of few millimeters: 5.7 ± 3.9 mm at 10 W, 3.7 ± 2.2 mm at 30 W, and 3.5 ± 2.4 mm at 50 W ( p = 0.3), without a significant correlation between power setting and mean necrosis short axis (rho = -0.28; p = 0.30). Good agreement was seen between pathologists ( k = 0.76; 95% confidence interval 0.55-0.98). Logistic regression analysis did not show associations between CT features and RFA response., Conclusions: RFA causes histologically evident damage with coagulative necrosis of a few millimeters in 80% of ex-vivo PDAC samples after chemotherapy and no clinical or pre-operative CT features can predict efficacy. Power settings do not correlate with the histological ablation area. These results are of relevance when employing RFA in vivo and planning clinical trials on its role in PDAC patients., Competing Interests: The authors declare no conflict of interest., (© 2022 The Authors. DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.)
- Published
- 2022
- Full Text
- View/download PDF
35. Could early tumour volume changes assessed on morphological MRI predict the response to chemoradiation therapy in locally-advanced rectal cancer?
- Author
-
Palmisano, A., Esposito, A., Di Chiara, A., Ambrosi, A., Passoni, P., Slim, N., Fiorino, C., Albarello, L., Di Muzio, N., Calandrino, R., Rosati, R., Del Maschio, A., De Cobelli, F., PALMISANO , ANNA, Palmisano, A., Esposito, A., Di Chiara, A., Ambrosi, A., Passoni, P., Slim, N., Fiorino, C., Albarello, L., Di Muzio, N., Calandrino, R., Rosati, R., Del Maschio, A., and De Cobelli, F.
- Subjects
Adult ,Male ,Radiology, Nuclear Medicine and Imaging ,Colorectal cancer ,Adenocarcinoma ,Drug Administration Schedule ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Prospective cohort study ,Aged ,medicine.diagnostic_test ,business.industry ,Rectal Neoplasms ,Cancer ,Magnetic resonance imaging ,General Medicine ,Chemoradiotherapy, Adjuvant ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Oxaliplatin ,Tumor Burden ,Treatment Outcome ,Fluorouracil ,030220 oncology & carcinogenesis ,Female ,Nuclear medicine ,business ,Chemoradiotherapy ,medicine.drug - Abstract
Aim: To investigate the potential role of an additional magnetic resonance imaging (MRI) examination performed during neoadjuvant chemoradiation therapy (CRT) in the prediction of pathological response in locally advanced rectal cancer (LARC). Material and methods: Forty-eight consecutive patients with LARC underwent neoadjuvant CRT. MRI studies at 1.5 T, including high-resolution T2-weighted sequences that were acquired parallel and perpendicular to the main axis of the tumour were performed before (preMRI), during (midMRI), and 6-8 weeks after the end of CRT (postMRI). Cancer volumes (Vpre, Vmid, Vpost) were drawn manually and the reduction rate calculated (ÎVmid, ÎVpost). According to Rödel's pathological tumour regression grade (TRG), patients were considered non-responders (NR; TRG0-2), partial responders (PR; TRG3), and complete responders (CR; TRG4). Multivariate regression analysis was performed to identify the best MRI predictors of NR, PR, and CR. Results: Twenty-five patients were considered PR (52%), 13 CR (27%), and 10 NR (22%). Tumour shrinkage mainly occurred shortly after CRT (ÎVmid: CR: 80±10% versus PR: 56±19% versus NR: 28±22%, p=2.2Ã10-16). Vmid, Vpost, ÎVmid, and ÎVpostcorrelated with TRG (p
- Published
- 2017
36. EP-1434 Neoadjuvant chemoradiotherapy in patients with esopageal or esophageal gastric junction cancer
- Author
-
Slim, N., primary, Tummineri, R., additional, Parise, P., additional, Mazza, E., additional, Albarello, L., additional, Puccetti, F., additional, Deli, A.M., additional, Incerti, E., additional, Azizi, M., additional, Dell'oca, I., additional, Cossu, A., additional, Reni, M., additional, Rosati, R., additional, Passoni, P., additional, and Di Muzio, N., additional
- Published
- 2019
- Full Text
- View/download PDF
37. The Prognostic Impact of Histology in Esophageal and Esophago-Gastric Junction Adenocarcinoma.
- Author
-
Fiocca R, Mastracci L, Lugaresi M, Grillo F, D'Errico A, Malvi D, Spaggiari P, Tomezzoli A, Albarello L, Ristimäki A, Bottiglieri L, Bonora E, Krishnadath KK, Raulli GD, Rosati R, Fumagalli Romario U, De Manzoni G, Räsänen J, and Mattioli S
- Abstract
Stage significantly affects survival of esophageal and esophago-gastric junction adenocarcinomas (EA/EGJAs), however, limited evidence for the prognostic role of histologic subtypes is available. The aim of the study was to describe a morphologic approach to EA/EGJAs and assess its discriminating prognostic power. Histologic slides from 299 neoadjuvant treatment-naïve EA/EGJAs, resected in five European Centers, were retrospectively reviewed. Morphologic features were re-assessed and correlated with survival. In glandular adenocarcinomas (240/299 cases-80%), WHO grade and tumors with a poorly differentiated component ≥6% were the most discriminant factors for survival (both p < 0.0001), distinguishing glandular well-differentiated from poorly differentiated adenocarcinomas. Two prognostically different histologic groups were identified: the lower risk group, comprising glandular well-differentiated (34.4%) and rare variants, such as mucinous muconodular carcinoma (2.7%) and diffuse desmoplastic carcinoma (1.7%), versus the higher risk group, comprising the glandular poorly differentiated subtype (45.8%), including invasive mucinous carcinoma (5.7%), diffuse anaplastic carcinoma (3%), mixed carcinoma (6.7%) (CSS p < 0.0001, DFS p = 0.001). Stage ( p < 0.0001), histologic groups ( p = 0.001), age >72 years ( p = 0.008), and vascular invasion ( p = 0.015) were prognostically significant in the multivariate analysis. The combined evaluation of stage/histologic group identified 5-year cancer-specific survival ranging from 87.6% (stage II, lower risk) to 14% (stage IVA, higher risk). Detailed characterization of histologic subtypes contributes to EA/EGJA prognostic prediction.
- Published
- 2021
- Full Text
- View/download PDF
38. Risk factors and clinical characteristics of early-onset colorectal cancer vs. late-onset colorectal cancer: a case-case study.
- Author
-
Di Leo M, Zuppardo RA, Puzzono M, Ditonno I, Mannucci A, Antoci G, Russo Raucci A, Patricelli MG, Elmore U, Tamburini AM, Albarello L, Azzolini F, Bonura GF, Esposito D, Fanti L, Notaristefano C, Viale E, Perea J, Testoni PA, Rosati R, and Cavestro GM
- Subjects
- Age of Onset, Humans, Incidence, Rectum, Retrospective Studies, Risk Factors, Young Adult, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms genetics
- Abstract
Background and Objectives: Early-onset colorectal cancer (eoCRC), defined as colorectal cancer (CRC) before the age of 50 is increasing in incidence. We evaluated exogenous and endogenous risk factors, and clinical features of eoCRC, compared to late-onset CRC (loCRC)., Methods: In this retrospective case-case study, patients were prospectively enrolled from 2015 to 2018. We collected clinical features (age, sex, time from symptom onset to diagnosis, symptoms, family history, smoking and alcohol habits, diabetes, BMI, and genetic analysis) and tumor characteristics. Independent risk factors for eoCRC and odds ratios (ORs) were identified., Results: Fifty-four eoCRCs and 494 loCRCs were enrolled. Patients with eoCRC experienced longer delay time from symptom onset to diagnosis: 40.7% were diagnosed within 6 months from symptoms onset, compared to 85.6% of patients with loCRC (P < 0.0001). They differed for sex, presence of symptoms, family history, smoking habit, alcohol intake, and BMI. Rectal localization was more closely associated with eoCRC (64.8%) than loCRC (34.5%, P < 0.0001). Family history of CRC was associated with eoCRC (OR = 8.8). When family history occurred with hereditary cancer syndromes, the OR for eoCRC increased to 21., Conclusion: In young adults with alarming symptoms, CRC must be suspected to avoid delay time from symptom onset to diagnosis and genetic risk assessment has to be evaluated. Smoking habits, alcohol intake, and BMI are not associated with eoCRC., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. EP-1449: Neoadjuvant chemoradiotherapy IG-IMRT PET based in esophageal or esophageal gastric junction cancer
- Author
-
Slim, N., primary, Gumina, C., additional, Parise, P., additional, Mazza, E., additional, Cossu, A., additional, Albarello, L., additional, Puccetti, F., additional, Reni, M., additional, Rosati, R., additional, Passoni, P., additional, and Di Muzio, N., additional
- Published
- 2018
- Full Text
- View/download PDF
40. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and 18F-FDG-PET/CT: Correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade
- Author
-
Giganti, F, De Cobelli, F, Canevari, C, Orsenigo, E, Gallivanone, F, Esposito, A, Castiglioni, I, Ambrosi, A, Albarello, L, Mazza, E, Gianolli, L, Staudacher, C, Del Maschio, A, Giganti F, De Cobelli F, Canevari C, Orsenigo E, Gallivanone F, Esposito A, CASTIGLIONI I, Ambrosi A, Albarello L, Mazza E, Gianolli L, Staudacher C, Del Maschio A, Giganti, F, De Cobelli, F, Canevari, C, Orsenigo, E, Gallivanone, F, Esposito, A, Castiglioni, I, Ambrosi, A, Albarello, L, Mazza, E, Gianolli, L, Staudacher, C, Del Maschio, A, Giganti F, De Cobelli F, Canevari C, Orsenigo E, Gallivanone F, Esposito A, CASTIGLIONI I, Ambrosi A, Albarello L, Mazza E, Gianolli L, Staudacher C, and Del Maschio A
- Abstract
Purpose: To assess whether changes in diffusionweighted MRI (DW-MRI) and 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), correlate with treatment response to neoadjuvant therapy (NT), as expressed by tumor regression grade (TRG), from locally advanced gastric adenocarcinoma (GA). Materials and Methods: Seventeen patients underwent both DW-MRI and 18F-FDG-PET/CT scans before and after the end of NT. Apparent diffusion coefficient (ADC) and mean standardized uptake value (SUV) corrected for partial volume effect (PVC-SUVBW-mean) were evaluated and compared with histopathological TRG. Results: Pre- And post-NT and percentage changes forADC and PVC-SUVBW-mean were assessed. Post-NT ADC and DADC showed a significant inverse correlation with TRG (r=-0.71; P=0.0011 and r=-0.78; P=0.00020, respectively) and significant differences in their mean values were found between responders (TRG 1-2-3) and nonresponders (TRG 4-5) (P=0.0009; P=0.000082, respectively). No correlations with TRG were found for pre-NT ADC and for all PVC-SUVBW-mean values as well as between DADC and D PVC-SUVBW-mean. Conclusion: DW-MRI seems more accurate than 18FFDG-PET/CT and ADC modifications may represent a reproducible tool to assess tumor response for GA
- Published
- 2014
41. Deletion of a pseudogene within a fragile site triggers the oncogenic expression of the mitotic CCSER1 gene.
- Author
-
Santoliquido BM, Frenquelli M, Contadini C, Bestetti S, Gaviraghi M, Barbieri E, De Antoni A, Albarello L, Amabile A, Gardini A, Lombardo A, Doglioni C, Provero P, Soddu S, Cittaro D, and Tonon G
- Subjects
- Cell Line, Cell Proliferation, Gene Expression Regulation, Neoplastic, Genomic Instability, HEK293 Cells, HeLa Cells, Humans, Mitosis, Pseudogenes, Cell Cycle Proteins genetics, Chromosome Fragile Sites, Gene Deletion, Up-Regulation
- Abstract
The oncogenic role of common fragile sites (CFS), focal and pervasive gaps in the cancer genome arising from replicative stress, remains controversial. Exploiting the TCGA dataset, we found that in most CFS the genes residing within the associated focal deletions are down-regulated, including proteins involved in tumour immune recognition. In a subset of CFS, however, the residing genes are surprisingly overexpressed. Within the most frequent CFS in this group, FRA4F, which is deleted in up to 18% of cancer cases and harbours the CCSER1 gene, we identified a region which includes an intronic, antisense pseudogene, TMSB4XP8. TMSB4XP8 focal ablation or transcriptional silencing elicits the overexpression of CCSER1 , through a cis-acting mechanism. CCSER1 overexpression increases proliferation and triggers centrosome amplifications, multinuclearity, and aberrant mitoses. Accordingly, FRA4F is associated in patient samples to mitotic genes deregulation and genomic instability. As a result, cells overexpressing CCSER1 become sensitive to the treatment with aurora kinase inhibitors. Our findings point to a novel tumourigenic mechanism where focal deletions increase the expression of a new class of "dormant" oncogenes., (© 2021 Santoliquido et al.)
- Published
- 2021
- Full Text
- View/download PDF
42. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes
- Author
-
Mennonna, D, Maccalli, C, Romano, M, Garavaglia, C, Capocefalo, F, Bordoni, R, Severgnini, M, De Bellis, G, Sidney, J, Sette, A, Gori, A, Longhi, R, Braga, M, Ghirardelli, L, Baldari, L, Orsenigo, E, Albarello, L, Zino, E, Fleischhauer, K, Mazzola, G, Ferrero, N, Amoroso, A, Casorati, G, Parmiani, G, Dellabona, P, Mennonna, Daniele, Maccalli, Cristina, Romano, Michele C., Garavaglia, Claudio, Capocefalo, Filippo, Bordoni, Roberta, Severgnini, Marco, De Bellis, Gianluca, Sidney, John, Sette, Alessandro, Gori, Alessandro, Longhi, Renato, Braga, Marco, Ghirardelli, Luca, Baldari, Ludovica, Orsenigo, Elena, Albarello, Luca, Zino, Elisabetta, Fleischhauer, Katharina, Mazzola, Gina, Ferrero, Norma, Amoroso, Antonio, Casorati, Giulia, Parmiani, Giorgio, Dellabona, Paolo, Mennonna, D, Maccalli, C, Romano, M, Garavaglia, C, Capocefalo, F, Bordoni, R, Severgnini, M, De Bellis, G, Sidney, J, Sette, A, Gori, A, Longhi, R, Braga, M, Ghirardelli, L, Baldari, L, Orsenigo, E, Albarello, L, Zino, E, Fleischhauer, K, Mazzola, G, Ferrero, N, Amoroso, A, Casorati, G, Parmiani, G, Dellabona, P, Mennonna, Daniele, Maccalli, Cristina, Romano, Michele C., Garavaglia, Claudio, Capocefalo, Filippo, Bordoni, Roberta, Severgnini, Marco, De Bellis, Gianluca, Sidney, John, Sette, Alessandro, Gori, Alessandro, Longhi, Renato, Braga, Marco, Ghirardelli, Luca, Baldari, Ludovica, Orsenigo, Elena, Albarello, Luca, Zino, Elisabetta, Fleischhauer, Katharina, Mazzola, Gina, Ferrero, Norma, Amoroso, Antonio, Casorati, Giulia, Parmiani, Giorgio, and Dellabona, Paolo
- Abstract
Objective Patient-specific (unique) tumour antigens, encoded by somatically mutated cancer genes, generate neoepitopes that are implicated in the induction of tumour-controlling T cell responses. Recent advancements in massive DNA sequencing combined with robust T cell epitope predictions have allowed their systematic identification in several malignancies. Design We undertook the identification of unique neoepitopes in colorectal cancers (CRCs) by using high-throughput sequencing of cDNAs expressed by standard cancer cell cultures, and by related cancer stem/initiating cells (CSCs) cultures, coupled with a reverse immunology approach not requiring human leukocyte antigen (HLA) allele-specific epitope predictions. Results Several unique mutated antigens of CRC, shared by standard cancer and related CSC cultures, were identified by this strategy. CD8+ and CD4+ T cells, either autologous to the patient or derived from HLA-matched healthy donors, were readily expanded in vitro by peptides spanning different cancer mutations and specifically recognised differentiated cancer cells and CSC cultures, expressing the mutations. Neoepitope-specific CD8+ T cell frequency was also increased in a patient, compared with healthy donors, supporting the occurrence of clonal expansion in vivo. Conclusions These results provide a proof-of-concept approach for the identification of unique neoepitopes that are immunogenic in patients with CRC and can also target T cells against the most aggressive CSC component.
- Published
- 2017
43. TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study
- Author
-
Rindi, G., Falconi, M., Klersy, C., Albarello, L., Boninsegna, L., Buchler, M. W., Capella, C., Caplin, M., Couvelard, A., Doglioni, C., Delle Fave, G., Fischer, L., Fusai, G., de Herder, W. W., Jann, H., Komminoth, P., de Krijger, R. R., La Rosa, S., Luong, T. V., Pape, U., Perren, A., Ruszniewski, P., Scarpa, A., Schmitt, A., Solcia, E., Wiedenmann, B., Rindi, G., Falconi, M., Klersy, C., Albarello, L., Boninsegna, L., Buchler, M. W., Capella, C., Caplin, M., Couvelard, A., Doglioni, C., Delle Fave, G., Fischer, L., Fusai, G., de Herder, W. W., Jann, H., Komminoth, P., de Krijger, R. R., La Rosa, S., Luong, T. V., Pape, U., Perren, A., Ruszniewski, P., Scarpa, A., Schmitt, A., Solcia, E., and Wiedenmann, B.
- Abstract
Background Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful TNM system for pancreatic neuroendocrine neoplasms. Methods The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All statistical tests were two-sided. Results Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; and stage IV HR of death = 160, 95% CI = 22.30 to 1143, P < .001). However, the UICC/AJCC/WHO 2010 TNM staging system compressed the disease into three differently populated classes, with most patients in stage I, and with the patients being equally distributed into stages II-III (statistically similar) and IV (with stage I as the reference; stage II HR of death = 9.57, 95% CI = 4.62 to 19.88, P < .001; stage III HR of death = 9.32, 95% CI = 3.69 to 23.53, P = .94; and stage IV HR of death = 30.84, 95% CI = 15.62 to 60.87, P < .001). Multivariable modeling indicated curative surgery, TNM staging, and grading were effective predictors of death, and grading was the second most effective independent predictor of survival in the absence of staging information. Though both TNM staging systems
- Published
- 2017
44. Italian consensus guidelines for chronic pancreatitis
- Author
-
Frulloni, L, Falconi, M, Gabbrielli, A, Gaia, E, Graziani, R, Pezzilli, R, Uomo, G, Andriulli, A, Balzano, G, Benini, L, Calculli, L, Campra, D, Capurso, G, Cavestro, Gm, De Angelis, C, Ghezzo, L, Manfredi, R, Malesci, A, Mariani, A, Mutignani, M, Ventrucci, M, Zamboni, G, Amodio, A, Vantini, I, Bassi, C, Delle Fave, G, Capurso, Iv, Magarini, F, Albarello, L, Alfieri, S, Anti, M, Arcidiacono, P, Baiocchi, L, Berretti, D, Boraschi, P, Buscarini, E, Carroccio, A, Celebrano, Mr, Casadei, R, Chilovi, F, Conigliaro, R, Dall'Oglio, L, De Boni, M, De Pretis, G, Di Priolo, S, Di Sebastiano PL, Doglietto, Gb, Filauro, M, Frieri, G, Fuini, A, Loriga, P, Macarri, G, Manes, G, Massucco, P, Milani, S, Pasquali, Claudio, Pederzoli, P, Pietrangeli, M, Rocca, R, Russello, D, Siquini, W, Traina, M, Veneroni, L, Zilli, M, Italian Association for the Study of the Pancreas, Frulloni L, Falconi M, Gabbrielli A, Gaia E, Graziani R, Pezzilli R, Uomo G, Andriulli A, Balzano G, Benini L, Calculli L, Campra D, Capurso G, Cavestro GM, De Angelis C, Ghezzo L, Manfredi R, Malesci A, Mariani A, Mutignani M, Ventrucci M, Zamboni G, Amodio A, Vantini I, Italian Association for the Study of the Pancreas (AISP), Bassi C, Delle Fave G, Capurso IV, Magarini F, Albarello L, Alfieri S, Anti M, Arcidiacono P, Baiocchi L, Berretti D, Boraschi P, Buscarini E, Carroccio A, Celebrano MR, Casadei R, Chilovi F, Conigliaro R, Dall'Oglio L, De Boni M, De Pretis G, Di Priolo S, Di Sebastiano PL, Doglietto GB, Filauro M, Frieri G, Fuini A, Loriga P, Macarri G, Manes G, Massucco P, Milani S, Pasquali C, Pederzoli P, Pietrangeli M, Rocca R, Russello D, Siquini W, Traina M, Veneroni L, Zilli M, Zamboni G., Frulloni, L, Falconi, M, Gabbrielli, A, Gaia, E, Graziani, R, Pezzilli, R, Uomo, G, Andriulli, A, Balzano, G, Benini, L, Calculli, L, Campra, D, Capurso, G, Cavestro, Gm, De Angelis, C, Ghezzo, L, Manfredi, R, Malesci, A, Mariani, A, Mutignani, M, Ventrucci, M, Zamboni, G, Amodio, A, Vantini, I, Italian Association for the Study of the Pancreas, (AISP), Bassi, C, Delle Fave, G, Capurso, Iv, Magarini, F, Albarello, L, Alfieri, S, Anti, M, Arcidiacono, P, Baiocchi, L, Berretti, D, Boraschi, P, Carroccio, A, Celebrano, Mr, Casadei, R, Chilovi, F, Conigliaro, R, Dall'Oglio, L, De Boni, M, De Pretis, G, Di Priolo, S, Di Sebastiano, Pl, Doglietto, Gb, Filauro, M, Frieri, G, Fuini, A, Macarri, G, Manes, G, Massucco, P, Milani, S, Pasquali, C, Pederzoli, P, Pietrangeli, M, Rocca, R, Russello, D, Siquini, W, Traina, M, Veneroni, L, Zilli, M, and Zamboni, G.
- Subjects
medicine.medical_specialty ,complications ,pancreatic supplements ,diagnostic imaging ,pancreatitis ,MEDLINE ,cholangiopancreatography ,chronic ,endoscopic retrograde ,pain ,quality of life ,radiography ,sphincterotomy ,steatorrhea ,surgery ,therapy ,ultrasonography ,Appropriate use ,guidelines ,chronica pancreatitis ,Pancreatitis, Chronic ,Pancreatitis, chronic ,Complications ,Surgery ,Medical imaging ,Medicine ,Humans ,Pancreatic stones ,Intensive care medicine ,Surgical treatment ,Hepatology ,medicine.diagnostic_test ,business.industry ,Pancreatitis ,Radiography ,Therapy ,Ultrasonography ,Cholangiopancreatography ,Sphincterotomy ,Diagnostic imaging ,Pain ,Quality of life ,Steatorrhea ,Pancreatic supplements ,Gastroenterology ,medicine.disease ,Endoscopy ,Pancreatic pain ,Italy ,CHRONIC PANCREATITIS ,Radiology ,business - Abstract
This paper gives practical guidelines for diagnosis and treatment of chronic pancreatitis. Statements have been elaborated by working teams of experts, by searching for and analysing the literature, and submitted to a consensus process by using a Delphi modified procedure. The statements report recommendations on clinical and nutritional approach, assessment of pancreatic function, treatment of exocrine pancreatic failure and of secondary diabetes, treatment of pain and prevention of painful relapses. Moreover, the role of endoscopy in approaching pancreatic pain, pancreatic stones, duct narrowing and dilation, and complications was considered. Recommendations for most appropriate use of various imaging techniques and of ultrasound endoscopy are reported. Finally, a group of recommendations are addressed to the surgical treatment, with definition of right indications, timing, most appropriate procedures and techniques in different clinical conditions and targets, and clinical and functional outcomes following surgery. © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. Keywords: Pancreatitis, chronic; Complications; Surgery; Radiography; Therapy; Ultrasonography; Cholangiopancreatography
- Published
- 2010
45. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients
- Author
-
SAGNELLI, Caterina, Uberti Foppa C, Galli L, PASQUALE, Giuseppe, COPPOLA, Nicola, Albarello L, Doglioni C, Lazzarin A, Sagnelli E., Sagnelli, Caterina, Uberti Foppa, C, Galli, L, Pasquale, Giuseppe, Coppola, Nicola, Albarello, L, Doglioni, C, Lazzarin, A, and Sagnelli, E.
- Published
- 2014
46. Prognostic role of c-myc amplification in pancreatic acinar cell carcinomas
- Author
-
La Rosa, S, Bernasconi, B, Tibiletti, Mg, Vanoli, A, Zang, L, Notohara, K, Albarello, L, Casnedi, S, Assi, A, and Sessa, F
- Published
- 2016
47. Histopathology of Non-IBD Colitis. A practical approach from the Italian Group for the study of the gastrointestinal tract (GIPAD).
- Author
-
Villanacci V, Reggiani-Bonetti L, Leoncini G, Parente P, Cadei M, Albarello L, Mandelli G, and Caputo A
- Subjects
- Humans, Italy epidemiology, Colitis diagnosis, Colitis etiology, Colitis, Microscopic, Inflammatory Bowel Diseases
- Abstract
Non-IBD colitides (NIBDC) are intestinal diseases clinically and endoscopically overlapping with Inflammatory Bowel Diseases (IBD), sometimes with a similar histological picture. NIBDC include entities such as infectious colitis, ischemic colitis, pseudomembranous colitis, eosinophilic colitis, autoimmune enterocolitis, segmental colitis associated with diverticulosis, drug-induced colitis, radiation-induced colitis, diversion colitis, and microscopic colitis, this last including two entities: collagenous and lymphocytic colitis. The knowledge of the most useful histological features and the main clinical data for each entity is mandatory in daily clinical practice, for correct pathological diagnosis and clinical management., (Copyright © 2021 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.)
- Published
- 2021
- Full Text
- View/download PDF
48. Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD).
- Author
-
Villanacci V, Reggiani-Bonetti L, Salviato T, Leoncini G, Cadei M, Albarello L, Caputo A, Aquilano MC, Battista S, and Parente P
- Subjects
- Humans, Italy epidemiology, Pathologists, Colitis, Inflammatory Bowel Diseases diagnosis
- Abstract
Inflammatory bowel diseases (IBDs) are lifelong disorders in which an interaction between genetic and environmental factors is involved. IBDs include two entities: Crohn's disease (CD) and ulcerative colitis (UC); these can be adequately diagnosed and distinguished with a correct methodological approach based on communicating exhaustive clinical, endoscopic and laboratory information to the pathologist and performing adequate bioptic sampling and precise morphological signs including crypt architecture, distribution of inflammation and granulomas, when present. IBD needs to be distinguished from non-IBD colitis, mostly at its onset. Moreover, IBDs are associated with an increased risk of developing colorectal adenocarcinoma. In daily pathological practice, correct diagnosis of IBD and its subclassification as well as a correct detection of dysplasia is imperative to establish the best therapeutic approach., (Copyright © 2021 Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology.)
- Published
- 2021
- Full Text
- View/download PDF
49. Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy
- Author
-
Pecorelli, N, Braga, M, Doglioni, C, Balzano, G, Reni, M, Cereda, S, Albarello, L, Castoldi, R, Capretti, G, Di Carlo, V, Pecorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, Albarello L, Castoldi R, Capretti G, Di Carlo V., Pecorelli, N, Braga, M, Doglioni, C, Balzano, G, Reni, M, Cereda, S, Albarello, L, Castoldi, R, Capretti, G, Di Carlo, V, Pecorelli N, Braga M, Doglioni C, Balzano G, Reni M, Cereda S, Albarello L, Castoldi R, Capretti G, and Di Carlo V.
- Abstract
Background: Preoperative chemotherapy (PCHT) has recently been proposed also in patients with resectable pancreatic adenocarcinoma. Few data are currently available on the impact of PCHT on short-term postoperative outcome after pancreatic resection. The objective of this study is to assess the impact of PCHT on pancreatic structure and short-term outcome after surgical resection. Methods: Fifty consecutive patients successfully underwent resection after PCHT. Each patient was matched with two control patients with pancreatic adenocarcinoma selected from our prospective electronic database. Match criteria were age (±3 years), gender, American Society of Anesthesiologist score, type of resection, pancreatic duct diameter (±1 mm), and tumor size (±5 mm). Primary endpoint was morbidity rate. Secondary endpoints were pancreatic parenchymal structure, mortality rate, and length of hospital stay (LOS). Results: Both degree of fibrosis and fatty infiltration of the pancreas were similar in the two groups. Overall morbidity rate was 48. 0 % in the PCHT group vs. 54. 0 % in the control group (p = 0. 37). Pancreatic fistula rate was 18. 0 % in the PCHT group vs. 25. 0 % in the control group (p = 0. 41). Mortality was 4. 0 % in the PCHT group vs. 2. 0 % in the control group (p = 0. 60). Mean LOS (days) was 12. 7 in the PCHT group vs. 12. 4 in the control group (p = 0. 74). There was no difference in resection margin status, while the rate of patients without nodal involvement was higher in the PCHT group (46. 0 vs. 23. 0 %, p = 0. 004). Conclusion: PCHT did not induce significant structural changes in pancreatic parenchyma and did not adversely affect short-term outcome after surgery.
- Published
- 2013
50. Gastroenteric neuroendocrine neoplasms classification: Comparison of prognostic models
- Author
-
Dolcetta Capuzzo A, Villa V, Albarello L, Franchi GM, Gemma M, Scavini M, Di Palo S, Orsenigo E, BOSI , EMANUELE, DOGLIONI , CLAUDIO, Manzoni MF, Dolcetta Capuzzo, A, Villa, V, Albarello, L, Franchi, Gm, Gemma, M, Scavini, M, Di Palo, S, Orsenigo, E, Bosi, Emanuele, Doglioni, Claudio, and Manzoni, Mf
- Abstract
BACKGROUND: Gastroenteric neuroendocrine neoplasms (GE-NENs) display highly variable clinical behavior. In an attempt to assess a better prognostic description, in 2010, the World Health Organization (WHO) updated its previous classification, and the European Neuroendocrine Tumors Society (ENETS) proposed a new grading and TNM-based staging system. In the current study, the authors evaluated the prognostic significance of these models and compared their efficacy in describing patients' long-term survival to assess the best prognostic model currently available for clinicians. METHODS: The study cohort was composed of 145 patients with extrapancreatic GE-NEN who were observed from 1986 to 2008 at a single center and were classified according to the WHO and ENETS classifications. Survival evaluations were performed using Kaplan-Meyer analyses on 131 patients. Only deaths from neoplasia were considered. A P value < .05 was considered significant. Prognostic efficacy was assessed by determining the Harrell concordance index (c-index). RESULTS: Both the 2010 WHO and the ENETS classification were able to efficiently divide patients into classes with different prognoses. According to the model comparison, the ENETS TNM-based staging system appeared to be the strongest. All combined models were effective prognostic predictors, but the model that included the 2010 WHO classification plus ENETS staging had a higher c-index. CONCLUSIONS: Both the 2010 WHO classification and the ENETS staging system are valid instruments for GE-NENs prognostic assessment, with TNM-based stage appearing to be the best available choice for clinicians, both alone and in association with other classifications.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.